FI
KROS icon

Fosun International’s Keros Therapeutics KROS Stock Holding History

Fosun International’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-83,545
Closed -$3.22M – 201
2020
Q3 		$3.22M Buy
+83,545
New +$3.31M 0.28% 50

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Fosun International's KROS Position: Q4 2020 in Review

Fosun International sold out of Keros Therapeutics (KROS) in Q4 2020, closing a stake of 83,545 shares — an estimated $3.22M sold.

Fosun International first reported a position in KROS in Q3 2020 and held it in 1 quarter. The position peaked at $3.22M in Q3 2020. 81 funds tracked by Wall St. Rank hold KROS as of Q4 2020.

  • Fosun International reported no remaining Keros Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Fosun International sold 83,545 Keros Therapeutics shares in Q4 2020, an estimated $3.22M.
  • Fosun International first reported a position in Keros Therapeutics in Q3 2020 and held it in 1 quarter.
  • Fosun International's Keros Therapeutics position peaked at $3.22M in Q3 2020.
  • 81 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2020.

Based on Fosun International's 13F filing for Q4 2020, filed 5 Feb 2021.